Amador Bioscience Expands to Belgium

The Biopharmaceutical Ecosystem Development Seminar jointly organized by the Provincial Government of Limburg, Belgium, Amador Bioscience Belgium and Hasselt University came to a successful conclusion. The goal was to discuss how to promote the development of new drug research and growth of the local, also marking the official establishment of Amador Bioscience Belgium.

Amador Bioscience is focusing on clinical pharmacology to drive the development of new drugs, providing full-chain services in clinical development that meet international standards. 

It has presently established operating facilities in China, United States, and Europe, and its customer base ranges from start-up biotechnology companies to multinational pharmaceutical companies. Up to now, the Amador team has successfully completed more than 200 market entry declarations (e.g. NDAs, BLAs, MAAs) for domestic and foreign customers in the United States and Europe. 

Amador’s clinical research business is to use its clinical pharmacology features and core advantages to make medical strategies more scientific, improve data quality, clinical development efficiency, and increase the success rate of listing.

Globalization, scienc,e and cutting-edge are the three keywords for the delivery of Amador's clinical research solutions.

Dr. Bing Wang, Chairman and Chief Executive Officer of Amador Bioscience introduced that globalization means that the delivered reports and application materials meet the requirements of the global drug regulatory authorities. 

The implementation of clinical research projects relies on Amador’s global team of experts by using science as the main motivator.

Clinical pharmacology guides the development of innovative drugs; medical strategies are more scientific, patient selection is more accurate, and the efficiency of clinical development can be improved dramatically.

Amador’s team has supported many first-in-class listings in the world, and their grasp of cutting-edge science can help more innovative drugs to succeed.

	Jos Lantmeeters, Governor of Limburg, Belgium: “The Health Campus brings together scientific research institutions, medical institutions, enterprises, local governments, and other advantageous resources. The industrial park is located on the campus of a university, and international companies can directly access The University of Health and Life Sciences, Biomedical Sciences, and Global Health have access to talent resources such as PhD and Masters. The arrival of Amador Bio will vigorously promote the local ecosystem and create new employment opportunities with a global focus.”
	Yi Haiping, director of Hangzhou Xiaoshan Investment Promotion Bureau: “The expert team of Amador Bioscience has also participated in the writing and revision of the relevant guidelines issued by the NMPA and the FDA, and has made great contributions. The government service department where the biology is located is very happy and proud of the good results achieved by the company, and we will continue to give strong support to the company.”
	Bing Wang, Chairman and Chief Executive Officer of Amador Bioscience: “Europe is a major player in the global innovative drug market, and the Amador Bio European Center will promote the exchange of new drug research and development between the United States, Europe, and China, and deepen mutual cooperation. The core team members of Amador have more than 20 years of innovative drugs. By developing industry experience and international vision, the establishment of the European Center has further improved Amador’s global platform, allowing us to provide better solutions for global new drug R&D companies, and also build a bridge for them to enter the global market.”
	Xiaomin Chen: “Amador will expand the market in Europe through joint ventures, strategic cooperation, and other means. We have been deeply engaged in translational science services and have formed a mature service model. This European hub will cooperate with the United States and China to provide one-stop translational science services around the world.”
Prof. Olivier Thas, Associate Dean of Hasselt University	Dr. Nidal Huniti, Head of Quantitative Pharmacology at Regeneron

The services of Amador will cover clinical pharmacology, Phase I clinical trials, bioanalytical laboratories, and clinical project management. A joint quantitative pharmacology graduate training program with Hasselt University will be set up.

Amador’s global “triangle” is completed, setting up a bridge for new pharma R&D to enter the global market The establishment of the Europe hub means that the first phase of Amador Bioscience’s global strategic plan has been fully implemented.